Go Pro
→ Earth's biggest energy source: near Grand Canyon (From Behind the Markets) (Ad)tc pixel Free AMS Stock Alerts

Advanced Medical Solutions Group (AMS) Competitors

Advanced Medical Solutions Group logo
GBX 280.50 0.00 (0.00%)
As of 12:33 PM Eastern
Compare

AMS vs. NIOX, TSTL, EKF, SPEC, and CREO

Should you buy Advanced Medical Solutions Group stock or one of its competitors? Advanced Medical Solutions Group's main competitors and comparable companies include NIOX Group (NIOX), Tristel (TSTL), EKF Diagnostics (EKF), INSPECS Group (SPEC), and Creo Medical Group (CREO). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment & supplies" industry.

How does Advanced Medical Solutions Group compare to NIOX Group?

NIOX Group (LON:NIOX) and Advanced Medical Solutions Group (LON:AMS) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, dividends, risk and media sentiment.

NIOX Group currently has a consensus price target of GBX 86, indicating a potential upside of 32.31%. Advanced Medical Solutions Group has a consensus price target of GBX 270.25, indicating a potential downside of 3.65%. Given NIOX Group's stronger consensus rating and higher possible upside, research analysts clearly believe NIOX Group is more favorable than Advanced Medical Solutions Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
NIOX Group
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Advanced Medical Solutions Group
0 Sell rating(s)
2 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.50

NIOX Group has a beta of 0.92, suggesting that its stock price is 8% less volatile than the broader market. Comparatively, Advanced Medical Solutions Group has a beta of 0.704, suggesting that its stock price is 30% less volatile than the broader market.

NIOX Group pays an annual dividend of GBX 1.25 per share and has a dividend yield of 1.9%. Advanced Medical Solutions Group pays an annual dividend of GBX 2.68 per share and has a dividend yield of 1.0%. NIOX Group pays out 76.2% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Advanced Medical Solutions Group pays out 59.3% of its earnings in the form of a dividend.

7.6% of NIOX Group shares are held by institutional investors. Comparatively, 21.5% of Advanced Medical Solutions Group shares are held by institutional investors. 5.1% of NIOX Group shares are held by insiders. Comparatively, 4.0% of Advanced Medical Solutions Group shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

NIOX Group has higher earnings, but lower revenue than Advanced Medical Solutions Group. NIOX Group is trading at a lower price-to-earnings ratio than Advanced Medical Solutions Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NIOX Group£48.70M5.62£995.88M£1.6439.63
Advanced Medical Solutions Group£228.94M2.67£11.22M£4.5262.06

NIOX Group has a net margin of 14.37% compared to Advanced Medical Solutions Group's net margin of 4.35%. NIOX Group's return on equity of 10.14% beat Advanced Medical Solutions Group's return on equity.

Company Net Margins Return on Equity Return on Assets
NIOX Group14.37% 10.14% 3.95%
Advanced Medical Solutions Group 4.35%3.87%2.35%

In the previous week, NIOX Group's average media sentiment score of 0.00 equaled Advanced Medical Solutions Group'saverage media sentiment score.

Company Overall Sentiment
NIOX Group Neutral
Advanced Medical Solutions Group Neutral

Summary

NIOX Group beats Advanced Medical Solutions Group on 10 of the 16 factors compared between the two stocks.

How does Advanced Medical Solutions Group compare to Tristel?

Tristel (LON:TSTL) and Advanced Medical Solutions Group (LON:AMS) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, earnings, dividends, profitability, risk, valuation, media sentiment and analyst recommendations.

22.4% of Tristel shares are held by institutional investors. Comparatively, 21.5% of Advanced Medical Solutions Group shares are held by institutional investors. 21.0% of Tristel shares are held by company insiders. Comparatively, 4.0% of Advanced Medical Solutions Group shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Advanced Medical Solutions Group has a consensus target price of GBX 270.25, indicating a potential downside of 3.65%. Given Advanced Medical Solutions Group's stronger consensus rating and higher probable upside, analysts plainly believe Advanced Medical Solutions Group is more favorable than Tristel.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Tristel
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Advanced Medical Solutions Group
0 Sell rating(s)
2 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.50

Tristel has a net margin of 15.88% compared to Advanced Medical Solutions Group's net margin of 4.35%. Tristel's return on equity of 23.64% beat Advanced Medical Solutions Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Tristel15.88% 23.64% 9.89%
Advanced Medical Solutions Group 4.35%3.87%2.35%

In the previous week, Tristel's average media sentiment score of 0.00 equaled Advanced Medical Solutions Group'saverage media sentiment score.

Company Overall Sentiment
Tristel Neutral
Advanced Medical Solutions Group Neutral

Advanced Medical Solutions Group has higher revenue and earnings than Tristel. Tristel is trading at a lower price-to-earnings ratio than Advanced Medical Solutions Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Tristel£49.54M3.93£6.54M£16.2424.94
Advanced Medical Solutions Group£228.94M2.67£11.22M£4.5262.06

Tristel has a beta of 0.344, indicating that its stock price is 66% less volatile than the broader market. Comparatively, Advanced Medical Solutions Group has a beta of 0.704, indicating that its stock price is 30% less volatile than the broader market.

Tristel pays an annual dividend of GBX 14.20 per share and has a dividend yield of 3.5%. Advanced Medical Solutions Group pays an annual dividend of GBX 2.68 per share and has a dividend yield of 1.0%. Tristel pays out 87.4% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Advanced Medical Solutions Group pays out 59.3% of its earnings in the form of a dividend.

Summary

Tristel and Advanced Medical Solutions Group tied by winning 8 of the 16 factors compared between the two stocks.

How does Advanced Medical Solutions Group compare to EKF Diagnostics?

EKF Diagnostics (LON:EKF) and Advanced Medical Solutions Group (LON:AMS) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, media sentiment, valuation, profitability, analyst recommendations, institutional ownership, risk and dividends.

Advanced Medical Solutions Group has a net margin of 4.35% compared to EKF Diagnostics' net margin of 4.12%. Advanced Medical Solutions Group's return on equity of 3.87% beat EKF Diagnostics' return on equity.

Company Net Margins Return on Equity Return on Assets
EKF Diagnostics4.12% 3.01% 5.27%
Advanced Medical Solutions Group 4.35%3.87%2.35%

EKF Diagnostics has a beta of 0.499, indicating that its stock price is 50% less volatile than the broader market. Comparatively, Advanced Medical Solutions Group has a beta of 0.704, indicating that its stock price is 30% less volatile than the broader market.

EKF Diagnostics currently has a consensus price target of GBX 35, indicating a potential upside of 36.72%. Advanced Medical Solutions Group has a consensus price target of GBX 270.25, indicating a potential downside of 3.65%. Given EKF Diagnostics' stronger consensus rating and higher possible upside, analysts clearly believe EKF Diagnostics is more favorable than Advanced Medical Solutions Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
EKF Diagnostics
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Advanced Medical Solutions Group
0 Sell rating(s)
2 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.50

Advanced Medical Solutions Group has higher revenue and earnings than EKF Diagnostics. EKF Diagnostics is trading at a lower price-to-earnings ratio than Advanced Medical Solutions Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
EKF Diagnostics£51.56M2.13£4.68M£0.4754.47
Advanced Medical Solutions Group£228.94M2.67£11.22M£4.5262.06

In the previous week, EKF Diagnostics' average media sentiment score of 0.00 equaled Advanced Medical Solutions Group'saverage media sentiment score.

Company Overall Sentiment
EKF Diagnostics Neutral
Advanced Medical Solutions Group Neutral

22.2% of EKF Diagnostics shares are held by institutional investors. Comparatively, 21.5% of Advanced Medical Solutions Group shares are held by institutional investors. 40.2% of EKF Diagnostics shares are held by insiders. Comparatively, 4.0% of Advanced Medical Solutions Group shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Advanced Medical Solutions Group beats EKF Diagnostics on 9 of the 14 factors compared between the two stocks.

How does Advanced Medical Solutions Group compare to INSPECS Group?

INSPECS Group (LON:SPEC) and Advanced Medical Solutions Group (LON:AMS) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, valuation, dividends, institutional ownership, analyst recommendations, risk, earnings and profitability.

Advanced Medical Solutions Group has higher revenue and earnings than INSPECS Group. INSPECS Group is trading at a lower price-to-earnings ratio than Advanced Medical Solutions Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
INSPECS Group£191.70M0.57-£4.11M-£9.40N/A
Advanced Medical Solutions Group£228.94M2.67£11.22M£4.5262.06

Advanced Medical Solutions Group has a net margin of 4.35% compared to INSPECS Group's net margin of -2.67%. Advanced Medical Solutions Group's return on equity of 3.87% beat INSPECS Group's return on equity.

Company Net Margins Return on Equity Return on Assets
INSPECS Group-2.67% -6.07% 0.45%
Advanced Medical Solutions Group 4.35%3.87%2.35%

INSPECS Group has a beta of 1.603, indicating that its share price is 60% more volatile than the broader market. Comparatively, Advanced Medical Solutions Group has a beta of 0.704, indicating that its share price is 30% less volatile than the broader market.

In the previous week, INSPECS Group had 4 more articles in the media than Advanced Medical Solutions Group. MarketBeat recorded 4 mentions for INSPECS Group and 0 mentions for Advanced Medical Solutions Group. Advanced Medical Solutions Group's average media sentiment score of 0.00 beat INSPECS Group's score of -0.52 indicating that Advanced Medical Solutions Group is being referred to more favorably in the news media.

Company Overall Sentiment
INSPECS Group Negative
Advanced Medical Solutions Group Neutral

INSPECS Group currently has a consensus price target of GBX 60, suggesting a potential downside of 40.00%. Advanced Medical Solutions Group has a consensus price target of GBX 270.25, suggesting a potential downside of 3.65%. Given Advanced Medical Solutions Group's higher probable upside, analysts plainly believe Advanced Medical Solutions Group is more favorable than INSPECS Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
INSPECS Group
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Advanced Medical Solutions Group
0 Sell rating(s)
2 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.50

0.2% of INSPECS Group shares are held by institutional investors. Comparatively, 21.5% of Advanced Medical Solutions Group shares are held by institutional investors. 19.6% of INSPECS Group shares are held by company insiders. Comparatively, 4.0% of Advanced Medical Solutions Group shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Advanced Medical Solutions Group beats INSPECS Group on 12 of the 16 factors compared between the two stocks.

How does Advanced Medical Solutions Group compare to Creo Medical Group?

Advanced Medical Solutions Group (LON:AMS) and Creo Medical Group (LON:CREO) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their media sentiment, risk, earnings, institutional ownership, dividends, analyst recommendations, valuation and profitability.

Advanced Medical Solutions Group has a beta of 0.704, indicating that its stock price is 30% less volatile than the broader market. Comparatively, Creo Medical Group has a beta of 1.563854, indicating that its stock price is 56% more volatile than the broader market.

Advanced Medical Solutions Group currently has a consensus price target of GBX 270.25, suggesting a potential downside of 3.65%. Creo Medical Group has a consensus price target of GBX 40, suggesting a potential upside of 224.54%. Given Creo Medical Group's higher probable upside, analysts plainly believe Creo Medical Group is more favorable than Advanced Medical Solutions Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Advanced Medical Solutions Group
0 Sell rating(s)
2 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.50
Creo Medical Group
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

21.5% of Advanced Medical Solutions Group shares are held by institutional investors. Comparatively, 44.1% of Creo Medical Group shares are held by institutional investors. 4.0% of Advanced Medical Solutions Group shares are held by insiders. Comparatively, 7.0% of Creo Medical Group shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Creo Medical Group had 1 more articles in the media than Advanced Medical Solutions Group. MarketBeat recorded 1 mentions for Creo Medical Group and 0 mentions for Advanced Medical Solutions Group. Creo Medical Group's average media sentiment score of 0.75 beat Advanced Medical Solutions Group's score of 0.00 indicating that Creo Medical Group is being referred to more favorably in the news media.

Company Overall Sentiment
Advanced Medical Solutions Group Neutral
Creo Medical Group Positive

Advanced Medical Solutions Group has higher revenue and earnings than Creo Medical Group. Creo Medical Group is trading at a lower price-to-earnings ratio than Advanced Medical Solutions Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Advanced Medical Solutions Group£228.94M2.67£11.22M£4.5262.06
Creo Medical Group£6M9.98-£25.04M£1.0012.33

Creo Medical Group has a net margin of 88.33% compared to Advanced Medical Solutions Group's net margin of 4.35%. Creo Medical Group's return on equity of 9.56% beat Advanced Medical Solutions Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Advanced Medical Solutions Group4.35% 3.87% 2.35%
Creo Medical Group 88.33%9.56%-20.09%

Summary

Creo Medical Group beats Advanced Medical Solutions Group on 9 of the 16 factors compared between the two stocks.

Get Advanced Medical Solutions Group News Delivered to You Automatically

Sign up to receive the latest news and ratings for AMS and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AMS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

AMS vs. The Competition

Export
MetricAdvanced Medical Solutions GroupHealthcare Equipment & Supplies IndustryHealthcare SectorLON Exchange
Market Cap£610.38M£5.58B£7.21B£2.86B
Dividend Yield1.02%1.78%2.56%6.22%
P/E Ratio62.0620.37213.24366.45
Price / Sales2.6772.48618.4183,880.78
Price / Cash7.8732.6977.3327.89
Price / Book2.475.8910.436.43
Net Income£11.22M£150.94M£3.49B£5.89B
7 Day Performance-0.18%-2.92%-2.99%17.15%
1 Month Performance-0.18%-3.20%0.02%0.13%
1 Year Performance36.17%7.93%20.19%20.11%

Advanced Medical Solutions Group Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
AMS
Advanced Medical Solutions Group
N/AGBX 280.50
flat		GBX 270.25
-3.7%		+34.2%£610.38M£228.94M62.0610
NIOX
NIOX Group
N/AGBX 67.60
flat		GBX 86
+27.2%		-9.7%£284.51M£48.70M41.2292
TSTL
Tristel
N/AGBX 415
+3.8%		N/A+13.5%£199.19M£49.54M25.55208
EKF
EKF Diagnostics
N/AGBX 25.30
flat		GBX 35
+38.3%		-13.9%£108.78M£51.56M53.83356
SPEC
INSPECS Group
0.7058 of 5 stars		GBX 92.75
-3.4%		GBX 60
-35.3%		+135.2%£101.26M£191.70MN/A1,673

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:AMS) was last updated on 9/10/2026 by MarketBeat.com Staff.
From Our Partners
Shocking AI prediction from the “Billionaire Whisperer"
Marc Chaikin's Power Gauge system flagged Micron before it soared 970 percent, Celestica before a 6,600 percen...
Chaikin Analytics | Sponsoredtc pixel
The trade I’ve been waiting for since 2011
Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...
Traders Agency | Sponsoredtc pixel
This looks like plywood. It's not.
AI data centers have a power problem nobody likes to talk about. A single rack of computers can now use more e...
Eagle Publishing | Sponsoredtc pixel
Why major institutions are piling into this digital asset now
BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...
Awesomely | Sponsoredtc pixel
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...
Investors Alley | Sponsoredtc pixel
Elon Musk’s Hushed FCC Filing. Sept 25th.
Elon Musk quietly filed a document with the federal government tied to artificial intelligence, one of the lar...
Paradigm Press | Sponsoredtc pixel
BlackRock and Vanguard already own THIS
Institutions own roughly 88 percent of an overlooked American oil and natural gas company. BlackRock holds 32 ...
Monument Traders Alliance | Sponsoredtc pixel
Why the Treasury still prices gold at 42 dollars an ounce
The U.S. Treasury still values its gold reserves at 42.22 dollars an ounce, a price set in 1973. Gold trades n...
Golden Portfolio | Sponsoredtc pixel